{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hirsch TI"],"funding":["NIDDK NIH HHS","This project was supported by National Institutes of Health 5T32HL007734 (Scott C. Fligor and Thomas I. Hirsch) and 2T32DK007754-22 (Savas T. Tsikis), the Richard and Sandra Cummings Research Fellowship of the Beth Israel Deaconess Medical Center Department of Surgery (Scott C. Fligor), Boston Children's Hospital Vascular Biology Program, Boston Children's Hospital Surgical Foundation, Hannah Lillie Fund; Maisie Ellis & Friends Fund, and Luke Raymond Celaya Research Fund. SterileCare (Markam, Ontario, Canada) provided financial support for statistical analysis and the 4% tetrasodium EDTA at no charge","NHLBI NIH HHS"],"pagination":["624-632"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11216891"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["48(5)"],"pubmed_abstract":["<h4>Background</h4>Selection of central venous catheter (CVC) lock solution impacts catheter mechanical complications and central line-associated bloodstream infections (CLABSIs) in pediatric patients with intestinal failure. Disadvantages of the current clinical standards, heparin and ethanol lock therapy (ELT), led to the discovery of new lock solutions. High-risk pediatric patients with intestinal failure who lost access to ELT during a recent shortage were offered enrollment in a compassionate use trial with 4% tetrasodium EDTA (T-EDTA), a lock solution with antimicrobial, antibiofilm, and antithrombotic properties.<h4>Methods</h4>We performed a descriptive cohort study including 14 high-risk pediatric patients with intestinal failure receiving 4% T-EDTA as a daily catheter lock soluti"],"journal":["JPEN. Journal of parenteral and enteral nutrition"],"pubmed_title":["Administration of 4% tetrasodium EDTA lock solution and central venous catheter complications in high-risk pediatric patients with intestinal failure: A retrospective cohort study."],"pmcid":["PMC11216891"],"funding_grant_id":["T32 HL007734","T32 DK007754","R24 DK091210"],"pubmed_authors":["Gura KM","Puder M","Wang SZ","DeVietro A","Carbeau S","Mitchell PD","Tsikis ST","Fligor SC","Hirsch TI","McClelland J","Carey AN"],"additional_accession":[]},"is_claimable":false,"name":"Administration of 4% tetrasodium EDTA lock solution and central venous catheter complications in high-risk pediatric patients with intestinal failure: A retrospective cohort study.","description":"<h4>Background</h4>Selection of central venous catheter (CVC) lock solution impacts catheter mechanical complications and central line-associated bloodstream infections (CLABSIs) in pediatric patients with intestinal failure. Disadvantages of the current clinical standards, heparin and ethanol lock therapy (ELT), led to the discovery of new lock solutions. High-risk pediatric patients with intestinal failure who lost access to ELT during a recent shortage were offered enrollment in a compassionate use trial with 4% tetrasodium EDTA (T-EDTA), a lock solution with antimicrobial, antibiofilm, and antithrombotic properties.<h4>Methods</h4>We performed a descriptive cohort study including 14 high-risk pediatric patients with intestinal failure receiving 4% T-EDTA as a daily catheter lock soluti","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-01T15:32:15.761Z","creation":"2026-04-08T13:46:50.581Z"},"accession":"S-EPMC11216891","cross_references":{"pubmed":["38837803"],"doi":["10.1002/jpen.2644"]}}